Donna Dambach is currently Senior Director, Head of Toxicology at Genentech, Inc.  The Toxicology group provides portfolio and program strategic and technical expertise from discovery through post-marketing phases including safety lead optimization and development candidate identification, the design and implementation of non-clinical development strategies for INDs/CTAs through NDAs/MAAs, and investigative toxicology support for programs through an Investigative Toxicology Laboratory.

Donna has been with Genentech for 13 years and has a combined 26 years of experience in both academia and industry as a comparative anatomic pathologist and as a discovery, investigative and regulatory toxicologist.

Donna received her Ph.D. from the Department of Toxicology from Rutgers University/University of Medicine and Dentistry of New Jersey.   Her doctoral research examined the role of inflammatory mediators and NFκB in the acetaminophen-induced model of acute oxidative-stress-mediated hepatotoxicity.  Donna received her veterinary degree (V.M.D.) from the University of Pennsylvania, completed a residency in comparative anatomic pathology at the University of Pennsylvania and attained board certification (American College of Veterinary Pathology) as a diplomate in the subspecialty of Comparative Anatomic Pathology.  For the last 9 years, Donna has been an active member of the IQ Consortium serving on the Board of Directors, the BOD Planning Committee and in the DruSafe (Preclinical Safety) Leadership Group where she has served on the Coordinating Committee and is current Chair.  She is a Fellow of the Academy of Toxicological Sciences and has authored or co-authored 60 peer-reviewed publications/book chapters and holds two patents for safety biomarkers.